Crystec Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Crystec Pharma is a private, platform technology company leveraging its proprietary mSAS® (modified Supercritical Anti-Solvent) process to engineer drug particles with high precision. The technology aims to solve key pharmaceutical challenges like poor solubility and stability, offering services to partners for drug reformulation and development. While likely pre-revenue or in early revenue from collaborations, its value proposition centers on de-risking and accelerating drug development programs for clients through its AI-enabled screening tool and scalable manufacturing platform.

Drug Delivery

Technology Platform

Proprietary mSAS® (modified Supercritical Anti-Solvent) supercritical fluid platform for precise particle engineering, enabling improved drug solubility, stability, and delivery. Includes AI tool (Prevista AI) for compound screening.

Opportunities

The large and growing need to solve poor drug solubility and bioavailability presents a significant market.

The platform's applicability to both small and large molecules, including for inhaled therapies, opens multiple avenues for collaboration and value creation.

Risk Factors

Revenue is dependent on the success of partner drug programs, which can fail for reasons unrelated to formulation.

The company must also compete with established and alternative particle engineering technologies to achieve widespread industry adoption.

Competitive Landscape

Crystec competes with other particle engineering technology providers and specialized CROs/CDMOs using techniques like spray drying, nano-milling, and other supercritical fluid processes. Its differentiation claims center on the stability, scalability, and versatility of its proprietary mSAS® platform.

More companies in Drug Delivery & Formulation →More companies in United Kingdom →